CAR-T Cell Therapy Platform
Immuno-Oncology Platform

CAR-T Cell Therapy Platform

CAR-T cell therapy, especially when directed against CD19 for B cell cancers, has demonstrated remarkable efficacy and received FDA approval in 2017. Nonetheless, despite its achievements, there exist challenges that must be addressed for CAR-T cells to realize their complete therapeutic potential against both solid tumors and hematological malignancies. Reaction Biology stands at the forefront of preclinical cancer immunotherapy, providing a wide array of CAR T-cell development services. Our dedicated platform, crafted by our team of immuno-oncology specialists, employs a blend of in vitro and in vivo studies to accelerate your research endeavors.

We offer a range of services, including:

  • Evaluating the potency and pharmacokinetics of your CAR T candidate within in vivo models of cancer biology
  • Assessing the in vitro cytotoxicity of your CAR T candidate across established cancer cell lines
  • Delving into the activation and memory status of CAR T-cells to illuminate their therapeutic potential
  • Testing the efficacy of CAR T candidates in xenograft models of solid tumors

With our platform’s capabilities, we empower you to refine and advance your therapeutic strategies, driving forward progress in cancer immunotherapy.

Strategies for successful
CAR T-cell therapy development

Barriers to effective CAR T-cell therapy encompass on-target off-tumor toxicities, limited anti-tumor activity across diverse tumor profiles, antigen escape, an immunosuppressive tumor microenvironment, and restricted trafficking and infiltration into tumors. Strategies to mitigate these challenges include:

  • Employing assays to evaluate tumor-specific post-translational modifications for refined targeting.
  • Assessing donor-to-donor heterogeneity in response to anti-tumor activity to optimize therapeutic efficacy.
  • Utilizing dual or tandem CARs to target multiple antigens concurrently.
  • Utilizing combination immunotherapy with CAR-T cells and checkpoint blockade, or engineering CAR-T cells to provide immunostimulatory signals.
  • Engineering CAR-T cells to enhance penetration through tumor stroma, or modulating chemokine receptors on CAR-T cells to respond to tumor-derived chemokines.

CAR T-cell therapy platform by Reaction Biology

  • Haematological malignancies
  • Solid tumor
Haematological malignancies

Our robust CD19 CAR-T cell assay suite is ideal for you to study the efficacy and pharmacokinetic properties by monitoring the anti-CD19 CAR T-cells in various preclinical in vitro and in vivo assay models.

Case I: Assess donor-to-donor variability of CD19 CAR T-cells in B cell leukemia model

Case II: Measure in vitro cytotoxicity of CD19 CAR T-cells in NALM-6 and MOLM-13 cell lines

Case III: Evaluate the activation and memory status of CD19 CAR T-cells via flow cytometry

Solid tumor

Our scientists have rigorously optimized the development of various in vivo and in vitro service portfolio to evaluate novel CAR T-cells, with a specific focus on addressing the challenges associated with CAR T therapy for solid tumors.

Case IV: Anti-tumor activity of CAR T-cells in NSG mice engrafted with a subcutaneous THP-1 xenograft tumor model